India Glioma Treatment Market

India Glioma Treatment Market Outlook 2031

• The industry in India was valued at US$ 95.3 Mn in 2022
• It is projected to grow at a CAGR of 8.8% from 2023 to 2031 and reach more than US$ 207.0 Mn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of brain tumors, including gliomas, is a major factor driving India glioma treatment market. Aging population, exposure to environmental toxins, and genetic predisposition are some of the factors contributing to increase in incidence of gliomas in India. Improvement in efficacy of glioma treatment due to advancements in technology and development of innovative treatments is likely to propel market expansion.

Availability of specialized medical professionals, including neurosurgeons, radiation oncologists, and medical oncologists, and establishment of specialized departments for the treatment of brain tumors in leading hospitals have made glioma treatment more accessible and effective in the country.

Surge in investment in research & development on new and innovative therapies for glioma treatment offers lucrative opportunities to market players. Biotechnology companies and research institutions are focusing on developing targeted therapies and immunotherapy drugs that can improve the survival rate of glioma patients.

India Glioma Treatment Market Introduction

Glioma treatment includes medications, devices, and therapies used to treat gliomas, a type of brain tumor. Gliomas are a serious health concern in India, with a high prevalence and mortality rate. The market includes a range of products and services, including glioma surgery, radiation therapy, glioma chemotherapy, and targeted therapy drugs.

Rise in prevalence of brain tumor, advancements in technology & treatments, growing availability of specialized medical professionals, and increase in investment in research & development are driving India glioma treatment market size.

Leading hospitals in India, such as the All India Institute of Medical Sciences (AIIMS), Tata Memorial Centre, and Apollo Hospitals, have specialized departments for the treatment of brain tumors, including gliomas.

Increase in Risk Factors

Glioma, a type of brain tumor, can be caused by various factors. Genetic mutations resulting from conditions such as retinoblastoma, Li-Fraumeni syndrome, tuberous sclerosis, neurofibromatosis 1&2, and Turcot syndrome are known to cause low-grade gliomas, but only a small percentage of glioma patients have a known genetic condition.

Exposure of the central nervous system to radiation, particularly therapeutic or high-dose radiation, has also been linked to increased incidence of subsequent brain tumors, including glioma.

N-nitroso compounds found in some cured meats, cigarette smoke, cosmetics, and nitrites or nitrates in the body have been linked to increased risk of developing glioma. Additionally, exposure to hazardous chemicals such as solvents, pesticides, oil products, rubber, and vinyl chloride during work can increase the risk of developing a brain tumor.

Age and gender are also factors, with glioma being more common in older adults and males. Dysfunction in the immune system may also play a role in the development of glioma. While limited, some studies have suggested that lifestyle factors such as smoking and poor diet may increase the risk of developing glioma.

Availability of Specialists Fueling India Glioma Treatment Market Demand

India has witnessed a steady increase in the availability of medical professionals who specialize in the treatment of glioma. According to the National Health Profile, the number of registered allopathic doctors in the country increased from 720,801 in 2015 to 785,386 in 2019. As of June 2022, the National Medical Commission reported that there are 1,308,009 allopathic doctors registered with State Medical Councils and the National Medical Commission, indicating a further increase in the availability of medical professionals in the country.

India has witnessed a rise in the number of highly skilled neurosurgeons, radiation oncologists, and medical oncologists who specialize in the treatment of glioma. Leading hospitals in the country, such as the All India Institute of Medical Sciences (AIIMS), Tata Memorial Centre, and Apollo Hospitals, have established specialized departments for the treatment of brain tumors, including glioma. These hospitals have cutting-edge facilities and experienced teams of specialists who provide comprehensive care to patients with glioma.

The country has witnessed increase in the number of medical colleges and institutions that offer specialized training in neurosurgery, radiation oncology, and medical oncology. This has resulted in a larger pool of highly qualified specialists who can provide specialized care for patients with glioma.

Extensive Treatment Required for Grade III and IV Gliomas

In terms of type, the high-grade segment accounted for the largest India glioma market share in 2022. This is ascribed to extensive treatment required for grade III and IV gliomas. A study published in the Indian Journal of Cancer revealed that grade III and grade IV gliomas make up the majority of all gliomas in India, with grade IV gliomas being the most prevalent. High-grade gliomas are aggressive and require immediate and comprehensive treatment, including surgery, radiation therapy, and chemotherapy.

The infiltrative and invasive nature of these tumors often makes complete surgical removal difficult. Hence, post-surgery radiation and chemotherapy are necessary to kill any remaining cancer cells and prevent the tumor from recurring. Advances in technology and development of targeted therapies have improved the efficacy of these treatments, leading to better outcomes for Indian patients with high-grade gliomas.

Advancements in Surgical Techniques

Based on treatment, the surgery segment dominated the glioma treatment market in India in 2022. Surgery is a key aspect of the treatment of gliomas in India. The number of glioma surgeries is expected to increase in the country in the next few years.

Major advancements have been made in surgical techniques for gliomas, including the use of minimally invasive procedures, laser therapy, and neuro-navigational systems.

Minimally invasive procedures involve smaller incisions, less tissue damage, and quicker recovery times, making them a more appealing option for patients. Laser therapy uses heat to kill cancer cells and can be used for removing tumors located in hard-to-reach areas. Neuro-navigational systems use imaging technology to create a real-time map of the brain, helping surgeons to precisely locate and remove tumors while minimizing the risk of damage to healthy brain tissue.

These advancements in surgical techniques have led to improved surgical outcomes, reduced recovery times, and lower risk of complications, making surgery an increasingly attractive option for patients seeking treatment for gliomas in India.

Analysis of Key Players

The glioma treatment market in India is fragmented, with the presence of large number of players. Leading companies in the country are focusing on investing in R&D on advanced treatments for glioma.

Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Intas Pharmaceuticals Ltd., Pfizer, Inc., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are the prominent players in the market.

Key Developments in India Glioma Treatment Industry

• In June 2023, Bristol-Myers Squibb began phase II clinical trials for Marizomib, a next-generation proteasome inhibitor derived from Salinispora tropica, to treat various conditions, including newly diagnosed malignant glioma, relapsed malignant glioma, and pediatric patients with diffuse intrinsic pontine glioma. Marizomib targets the 20S proteasome and can be given orally or intravenously. It is classified as a bicyclic beta-lactone gamma-lactam compound.
• In February 2023, Roche launched two new antibodies to assist healthcare professionals in identifying the mutation status of patients with brain cancer. The IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody are designed to accurately identify the mutation status of IDH1 and ATRX genes in gliomas, the most common type of brain tumors in adults. These antibodies will improve diagnostic precision and guide treatment decisions, ultimately resulting in better patient outcomes. Roche's new antibodies are expected to enhance the identification of mutation status in brain cancer patients, providing greater insight into their condition and improving the accuracy of diagnosis.
• In May 2023, F. Hoffmann-La Roche began conducting phase II clinical trials of Cobimetinib fumarate for the treatment of glioma, with a 23% phase transition success rate (PTSR) benchmark for progressing to phase III. The drug, marketed as Cotellic, is primarily used in combination with vemurafenib for unresectable or metastatic melanoma with specific mutations. Furthermore, Cobimetinib is being investigated for various other indications, including arteriovenous malformations, leukemia, lung cancer, ovarian cancer, pediatric glioma, and multiple other malignancies.
• In June 2023, The Intraoperative Radiation Therapy (IORT) procedure, a novel treatment in India, was successfully performed on a 41-year-old patient with recurrent glioblastoma at Fortis Hospital Bannerghatta. The patient had a prior history of weakness in the left upper and lower limbs and experienced a slight imbalance while walking.

Each of the prominent players has been profiled in India glioma treatment market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

India Glioma Treatment Market Snapshot